A State-of-the-Science Conference for Frontline Health Professionals, Sponsored by Collaborating Federal Health Agencies

A Comparison of Adverse Events and Quality of Life Before and After Switching from Kaletra^TM Soft-gel to Kaletra^TM Tablets in an African American Cohort
M. Keith Rawlings, MD¹, McGhee TA², Casey-Bailey S¹, Pasley M^3
1AIDS ARMS Inc, Dallas, TX; ²Absolute Care Medical Center, Atlanta, GA, Abbott Laboratories³

Amelioration of Human Immunodeficiency Virus (HIV)-Associated Neuropathic Pain with Spinal Cord Stimulation (SCS): Case Reports
Gary Thomas, MD¹, Allison Foster, PhD^2
1Comprehensive Pain Management, New York, NY, ²Boston Scientific, Valencia, CA

Case Study HIVAN and IgA Nephropathy as a Cause of Chronic Kidney Disease
Jennifer Klein FNP, Edna Toubes Klingler MD, Ejeanée Queen FNP, M. Keith Rawlings MD
Peabody Health Center, AIDS Arms Inc., Dallas, TX

Changing Lives with "A New Attitude"
Dr. Karen Gordon-Boyle¹, Barbara Cicatelli², Jairo Pedraza^2
1USAID/ GHARP (The Guyana HIV/AIDS Reduction and Prevention Program), ²Cicatelli Associates Inc

Comprehensive Care Clinic Visits are Associated with Better Control of HIV
Tuyen Hoang, PhD¹, Matthew Goetz, MD¹, Elizabeth Yano, PhD¹, Barbara Rossman, PhD¹, Henry Anaya, PhD¹, Herschel Knapp, PhD¹, Allen Gifford, MD², Steven Asch, MD^1
1HSR&D, VA GLA HEALTHCARE SYSTEM, ²VA BEDFORD HEALTHCARE SYSTEM

Darunavir in Combination With Other Medications: Pharmacokinetic Interactions
Raymond Pecini
Tibotec Therapeutics

Darunavir Resistance-Associated Mutations: Prevalence in Samples Received for Routine Clinical Resistance Testing
Alex Rinehart
Tibotec Therapeutics

Delivery of Clinical Pharmacist Services (CPS) into a High Risk OB/GYNE (HROBG) Clinic
Rupali Jain, PharmD¹, Doris Carroll, BSN², Mariela Diaz-Linares, PharmD¹, Ronald Hershow, MD³, Mark Vajaranant, MD^4
1Pharmacy Practice, University of Illinois at Chicago, ²College of Medicine, Section of Infectious Diseases, University of Illinois at Chicago, ³University of Illinois at Chicago, School of Public Health, ⁴Obstetrics/Gynecology, University of Illinois at Chicago

Efficacy of Tenofovir-Emtricitabine and Boosted Atazanavir Combination in the Treatment of HIV-Infected Patients Naïve to Antiretroviral Therapy
Catherine Chien, MD¹, Homayoon Khanlou, MD¹, Marjan Javanbakht, PhD², Paul DenOuden, MD¹, Parveen Kaur, MD¹, Alen Voskanian, MD¹, Charles Farthing, MD^1
1Medicine, AIDS Healthcare Foundation, ²Epidemiology, Univercity of California at Los Angeles

End-of-Life Care Discussions: Are They Relevant Anymore?
Katie Mosack, PhD
University of Wisconsin-Milwaukee

HIV Care A Small Clinic Perspective
Michael Cynamon, MD
Medicine, VAMC Syracuse

HIV Testing in Primary C Care, Behavioral Health and Emergency Departments:
Are Those at Risk Really Being Tested?
Judy Shaw, MS
Section of Infectious Disease, Samuel S. Stratton VAMC

Host-Driven Clearance of HIV Infection without Antiretroviral Therapy
Wenyuan Lin, MPH, Swati Rao, MD, Ashwani K. Singal, MD, Meenakshi Zaidi, MD, Pooja Motwani, MD, Samia Ahmed, MD, Truptesh H. Kothari, MD, Aelaf Worku, MD, MPH, Norbert Bräu, MD, MBA
Bronx VA Medical Center, Medical Program & Mount Sinai School of Medicine, Department of Medicine, New York NY

How Physicians Access and Use the Federal Treatment Guidelines
Cynthia Cadden, MSN¹, Robb Heier, PhD¹, Gale Dutcher, MS², Cynthia Love, MS^2
1AIDSinfo, ²National Library of Medicine

Improving Team Approaches to the Pregnant HIV+ Patient
Marla Shauer, MSN
Womens Services, Washington Hospital Center

Incorporating Client Focus Groups in Improving HIV Care
Hela Issaq, MPH
HIV ACCESS & The Family Care Network

Increasing Incidence of Colateral Cancer in the HIV Atlanta VA Cohort Study (HAVACS)
Jodie Guest, PhD, Abeer Moanna, MD, David Rimland, MD
Atlanta VA Medical Center and Emory University School of Medicine

Long-term Hepatic Safety of Protease Inhibitors Including Lopinavir/Ritonavir
Containing Regimens in the Treatment of HIV-HBV Co-Infected Patients
Homayoon Khanlou¹, Ashwaq Hermes², Richard A Rode², Rick A Stryker², Charles Farthing^1
1 AIDS Healthcare Foundation, Los Angeles, CA, United States; ² Abbott Laboratories, Abbott Park, IL, United States

Newly Diagnosed HIV Infection in the Era of HAART: Age, Survival, and Serum Markers
VijayLaxmi Misra, MD¹, Zeenat Naqvi, MD¹, John Eng, MD², Julie Williams, RN¹, Sheldon T. Brown, MD¹, Norbert Brau, MD^1
1I.D. Section, Bronx VA Medical Center, ²Medical Program, Bronx VA Medical Center

Non-Hodgkin's Lymphoma (NHL) of the Pituitary Initially Presenting with Panhypopituitarism and Report of a Single Institution Experience with Primary CNS Lymphoma (PCNSL) Between 1998-2007
Kelly A. Shimabukuro MD¹, Joseph Caperna MD¹, Erin Reid MD^2
1Owen Clinic UCSD Medical Center, ²Moores Cancer Center UCSD Medical Center

Outcomes in Real Practice with Comprehensive Care in a VA in 2006
Sandra Paez
VA New Jersey

Project HOPE: Hospital Visit is an Opportunity for Prevention and Engagement with HIV-positive Crack Users
Lisa Metsch¹, Carlos del Rio², Allan Rodriguez¹, Tanisha Sullivan², Gabe Cardenas¹, Lauren Gooden¹, Margaret Pereyra¹, Christine Bell², Toye Brewer¹, Tamy Kuper¹, Sarah Lewis³, Richard Rothenberg^2
1University of Miami Miller School of Medicine, ²Emory University School of Medicine, ³Barry University

Recent Drug Use, Homelessness and Increased Short-term Mortality in People with HIV and Alcohol Problems
Alexander Walley, MD
Boston Medical Center

Report of a Solitary Renal Aspergilloma in an AIDS patient: Nearly two year survival after successful treatment with nephrectomy
Joseph Caperna MD
Owen Clinic UCSD Medical Center

Seronegative Acute Hepatitis C Mimicking HAART-Induced Hepatotoxicity
Olga Ali, MS¹, Kimberly Summers, PhD¹, Gregory Anstead, MD^1
1Infectious Disease, South Texas Veterans Health Care System

Similar Changes in Metabolic Parameters of Darunavir and Atazanavir, Each Co-administered With Low-dose Ritonavir in Healthy Volunteers
Frank Tomaka
Tibotec Inc.

The Clinical Utility, Safety, and Tolerability of Poly L-lactic Acid Injections for HIV-Related Facial Lipoatrophy at the San Francisco VA Medical Center
Harry Lampiris, MD¹, Cindy Burt, RN², Heather Sourthwell, AS³, Mai Vu, PharmD⁴, Thea Mauro, MD⁵, Isaac Neuhaus, MD⁵, Phyllis Tien, MD^1
1Medicine/Infectious Disease Section, San Francisco VA Medical Center, ²Nursing, San Francisco VA Medical Center, ³Metabolism Section, San Francisco VA Medical Center, ⁴Pharmacy, San Francisco VA Medical Center, ⁵Dermatology, San Francisco VA Medical Center

TMC125 in Combination With Medications Commonly Used in HIV Infection: Summary of Drug-Drug Interactions
Deb Israel
Tibotec Therapeutics

TMC125 in Treatment-Experienced Patients: An Update
Peter Shalit
Swedish Medical Center

Use of iMedConsent to Implement Routine HIV Testing at a VA Medical Center
Beverly VanMetre, MS
VA Medical Center Martinsburg, WV, Department of Veterans Affairs

Utilization of an HIV Clinical Case Registry, as an Outcome Indicator, in a Nurse Managed Medication Adherence Program
Karen W. Cervino, RN, MS, ACRN and Janet C. Novak, RN, MA, ACRN
VA Maryland Health Care System, Baltimore, MD

Week 48 antiretroviral (ARV) response to darunavir (TMC114)/ritonavir and etravirine (TMC125) combination in patients with high level viral resistance
Marta Boffito¹, Alan Winston¹, Akil Jackson¹, Carl Fletcher¹, Anton Pozniak¹, Mark Nelson¹, Graeme Moyle¹, Richard Hoetelmans², Diego Miralles², Brian Gazzard^1
1Chelsea & Westminster Hospital, ²Tibotec BVBA